Home / Stocks / Divi S Laboratories Ltd
DIVISLAB

Divi S Laboratories Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹11,178.0

Change

+129.0 (1.17%)

Open

₹11,060.0

Prev. Close

₹11,049.0

Day High

₹11,178.0

Day Low

₹10,965.0

Volume Analysis

Traded

619,182

Delivered

411,330

Delivery %

66.43%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (38.0%)

Weaknesses (0)

No signal for this stock

Opportunities (1)

  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹11,462.0 ₹11,320.0 ₹11,249.0 ₹11,107.0 ₹11,036.0 ₹10,894.0 ₹10,823.0
Fibonacci ₹11,320.0 ₹11,238.63 ₹11,188.37 ₹11,107.0 ₹11,025.63 ₹10,975.37 ₹10,894.0
Camarilla ₹11,236.58 ₹11,217.05 ₹11,197.53 ₹11,107.0 ₹11,158.48 ₹11,138.95 ₹11,119.43

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+76.2%

1 Week

-2.67%

1 Month

+21.63%

3 Months

+30.02%

6 Months

+62.31%

1 Year

+72.97%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹1,214.75

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

16.16%

Net margin 27.59% × asset turnover 0.48x × equity multiplier 1.22x

Company Overview

Sector

Healthcare

Market Cap

₹294,139 Cr

P/E (TTM)

86.1

ROE

16.5%

Book Value

₹678.0

Face Value

₹2.0

Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.

TopFund Analysis

Divi S Laboratories Ltd holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 69/100. The strongest factor is Financial Strength (100/100), while Valuation (1/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (38.0%). FII holding has been rising.

TopFund Score — Fundamentals Quality

69/100 — Good

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

45

Valuation

1

Cash Flow

42

Corporate Governance

90

Momentum

88

Institutional Ownership

60

Business Quality

90

Risk & Volatility

94

Liquidity

85

From Screener.in

  • +Company is almost debt free.
  • +Company has been maintaining a healthy dividend payout of 39.0%
  • −Stock is trading at 16.3 times its book value
  • −The company has delivered a poor sales growth of 8.67% over past five years.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Submission of transcript of Q2Fy27 earnings call held on November 07, 2026.

Audio recording of Q2 FY27 earnings conference call uploaded on November 07, 2026.

Divi's Labs reported Q2 FY27 consolidated income of Rs 3,770 crore and PAT of Rs 1,127 crore.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 1,909 1,855 2,303 2,118 2,338 2,319 2,585 2,410 2,715 2,604 2,831 3,080 3,676
Expenses + 1,430 1,366 1,572 1,496 1,622 1,576 1,699 1,681 1,827 1,714 1,897 1,825 2,110
Operating Profit 479 489 731 622 716 743 886 729 888 890 934 1,255 1,566
OPM % 25.0% 26.0% 32.0% 29.0% 31.0% 32.0% 34.0% 30.0% 33.0% 34.0% 33.0% 41.0% 43.0%
Other Income + 86 95 79 79 106 82 86 119 145 14 155 64 94
Interest 1 0 2 0 1 0 1 3 8 6 6 6 13
Depreciation 95 95 95 97 99 99 107 112 113 118 120 133 142
Profit before tax 469 489 713 604 722 726 864 733 912 780 963 1,180 1,505
Tax % 26.0% 27.0% 25.0% 29.0% 29.0% 19.0% 23.0% 26.0% 24.0% 25.0% 22.0% 24.0% 25.0%
Net Profit + 348 358 538 430 510 589 662 545 689 583 751 902 1,127
EPS in Rs 13 13 20 16 19 22 25 21 26 22 28 34 42
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 3 9 18 19 22 25 12 14 16 12 10 28 35

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 3,115 3,776 4,064 3,891 4,946 5,394 6,969 8,960 7,768 7,845 9,360 10,560 12,191
Expenses + 1,942 2,354 2,615 2,622 3,072 3,568 4,102 5,075 5,397 5,635 6,387 7,118 7,546
Operating Profit 1,173 1,423 1,450 1,269 1,874 1,826 2,867 3,885 2,370 2,210 2,973 3,442 4,645
OPM % 38.0% 38.0% 36.0% 33.0% 38.0% 34.0% 41.0% 43.0% 31.0% 28.0% 32.0% 33.0% 38.0%
Other Income + 38 93 72 107 154 186 57 112 344 335 348 433 327
Interest 3 5 3 2 5 7 2 2 2 4 3 24 31
Depreciation 136 118 123 142 169 186 256 312 343 378 402 463 513
Profit before tax 1,072 1,393 1,395 1,231 1,855 1,819 2,666 3,684 2,369 2,163 2,916 3,388 4,428
Tax % 21.0% 19.0% 24.0% 29.0% 27.0% 24.0% 26.0% 20.0% 23.0% 26.0% 25.0% 24.0% —
Net Profit + 852 1,126 1,060 877 1,353 1,377 1,984 2,960 1,823 1,600 2,191 2,568 3,363
EPS in Rs 32 42 40 33 51 52 75 112 69 60 83 97 127
Dividend Payout % 31.0% 24.0% 25.0% 30.0% 31.0% 31.0% 27.0% 27.0% 44.0% 50.0% 36.0% 31.0% —
Sales growth 23 21 8 -4 27 9 29 29 -13 1 19 13 22

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 3,469 4,240 5,304 5,872 6,904 7,257 9,242 11,675 12,714 13,518 14,916 16,708 17,944
Borrowings + 27 42 36 63 106 39 5 4 3 3 4 7 6
Other Liabilities + 883 562 762 797 973 1,183 1,471 1,628 1,654 1,886 1,948 3,251 3,961
Total Liabilities 4,405 4,898 6,155 6,785 8,036 8,531 10,771 13,360 14,425 15,460 16,921 20,019 21,964
Fixed Assets + 1,309 1,439 1,559 1,996 2,088 2,782 3,704 4,325 4,723 4,739 5,442 6,528 7,473
CWIP 218 264 444 120 492 920 711 470 212 778 1,022 2,113 1,638
Investments 733 803 1,631 1,889 1,946 971 0 72 77 82 65 69 71
Other Assets + 2,145 2,392 2,521 2,780 3,511 3,858 6,356 8,493 9,413 9,861 10,392 11,309 12,782
Total Assets 4,405 4,898 6,155 6,785 8,036 8,531 10,771 13,360 14,425 15,460 16,921 20,019 21,964
Equity Capital 27 53 53 53 53 53 53 53 53 53 53 53 53

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 826 1,038 1,150 776 954 1,216 1,947 1,912 2,460 1,261 1,653 2,738
Cash from Investing Activity + -521 -406 -1,140 -478 -685 -83 75 -2,195 -2,708 -269 -804 -2,219
Cash from Financing Activity + -303 -631 2 -314 -246 -1,091 -35 -532 -797 -799 -799 -804
Net Cash Flow 3 0 13 -17 23 41 1,987 -816 -1,045 193 50 -285
Free Cash Flow 519 642 774 502 221 33 1,037 1,199 1,987 258 215 221
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 88 91 100 82 77 91 90 66 124 74 83 105

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 51.92% → 51.87%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 11.33% 11.19% 10.17% 9.79% 9.58% 9.39% 9.32% 8.96% 8.75% 8.61% 8.53% 8.58%
Promoters 51.92% 51.92% 51.89% 51.89% 51.89% 51.89% 51.88% 51.88% 51.88% 51.88% 51.88% 51.87%
Government 0.1% 0.1% 0.1% 0.09% 0.09% 0.09% 0.09% 0.09% 0.09% 0.09% 0.09% 0.09%
FII 14.85% 14.68% 16.16% 17.25% 17.98% 18.01% 19.74% 19.39% 20.08% 20.29% 20.19% 20.38%
DII 21.78% 22.1% 21.66% 20.98% 20.44% 20.63% 18.96% 19.68% 19.18% 19.13% 19.29% 19.08%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Divi S Laboratories Ltd (this stock) 294,139 86.1 16.34 16.5%
Torrent Pharmaceuticals L 177,632 81.8 9.67 27.4%
Sun Pharmaceutical Ind L 451,075 36.7 5.05 16.0%
Apollo Hospitals Enter. L 125,893 55.6 11.86 21.5%
Laurus Labs Limited 125,380 93.6 20.73 18.3%
Zydus Lifesciences Ltd 118,693 26.2 4.27 21.2%
Dr. Reddy S Laboratories 115,092 41.1 2.96 11.2%

Which Mutual Funds Hold Divi S Laboratories Ltd?

Frequently Asked Questions about Divi S Laboratories Ltd

Community Sentiment

What are other investors saying about Divi S Laboratories Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.